• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

镰状细胞病患者与健康黑人对照者凝血和纤溶的变化。

Changes in coagulation and fibrinolysis in patients with sickle cell disease compared with healthy black controls.

作者信息

Hagger D, Wolff S, Owen J, Samson D

机构信息

Department of Haematology, Charing Cross and Westminister Medical School, London, UK.

出版信息

Blood Coagul Fibrinolysis. 1995 Apr;6(2):93-9. doi: 10.1097/00001721-199504000-00001.

DOI:10.1097/00001721-199504000-00001
PMID:7605884
Abstract

Seventeen parameters of coagulation and fibrinolysis were measured in 33 patients with sickle cell disease; 30 were tested in steady state (SS) and 19 in crisis (Cr). There were 16 patients in both groups. The same parameters were measured in 16 controls of similar ethnic origin (Black controls; BC) and 20 Caucasian controls (CC), all with HbA only. Highly significant differences (P < 0.001) between Black and Caucasian control groups were noted for: fibrinogen, fibrinopeptide-A (FPA), beta-thromboglobulin (beta TG) and D-dimer. Significant differences (P < 0.03) in plasminogen activator inhibitor (PAI) and functional antithrombin III levels were also noted. Results of the sickle cell patients were therefore compared with those of the Black controls. Sickle cell patients in SS had raised v Wf compared with BC, which increased further during Cr (P = 0.001), but showed no significant increase in fibrinogen. Functional protein C was reduced in SS (P = 0.004) but with no further fall in Cr, while free protein S was normal in SS but reduced in Cr (P = 0.02). Total protein S and ATIII were normal in SS and Cr. FPA and beta TG were not significantly raised in SS or Cr compared with BC. There were, however, highly significant increases in D-dimer and thrombin-antithrombin complexes (TAT) in both SS and Cr compared with BC (P < 0.001 for SS and Cr vs BC). Thus significant activation of coagulation with consequent increase in fibrinolysis occurs during both the sickle cell crisis and in the steady state.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

对33例镰状细胞病患者的17项凝血和纤维蛋白溶解参数进行了测量;30例处于稳定状态(SS),19例处于危象期(Cr)。两组中有16例患者相同。对16名种族相似的黑人对照组(BC)和20名白人对照组(CC)(均仅含血红蛋白A)测量了相同参数。黑人与白人对照组之间在纤维蛋白原、纤维蛋白肽A(FPA)、β-血小板球蛋白(βTG)和D-二聚体方面存在高度显著差异(P < 0.001)。在纤溶酶原激活物抑制剂(PAI)和功能性抗凝血酶III水平上也存在显著差异(P < 0.03)。因此,将镰状细胞病患者的结果与黑人对照组进行了比较。处于SS期的镰状细胞病患者与BC相比,血管性血友病因子(vWf)升高,在Cr期进一步升高(P = 0.001),但纤维蛋白原无显著增加。功能性蛋白C在SS期降低(P = 0.004),但在Cr期无进一步下降,而游离蛋白S在SS期正常,但在Cr期降低(P = 0.02)。总蛋白S和抗凝血酶III在SS期和Cr期均正常。与BC相比,FPA和βTG在SS期或Cr期均未显著升高。然而,与BC相比,SS期和Cr期的D-二聚体和凝血酶-抗凝血酶复合物(TAT)均有高度显著增加(SS期和Cr期与BC相比,P < 0.001)。因此,在镰状细胞危象期和稳定状态下均发生了显著的凝血激活及随之而来的纤维蛋白溶解增加。(摘要截选至250字)

相似文献

1
Changes in coagulation and fibrinolysis in patients with sickle cell disease compared with healthy black controls.镰状细胞病患者与健康黑人对照者凝血和纤溶的变化。
Blood Coagul Fibrinolysis. 1995 Apr;6(2):93-9. doi: 10.1097/00001721-199504000-00001.
2
Abnormalities of coagulation and fibrinolysis in homozygous sickle cell disease.纯合子镰状细胞病的凝血和纤维蛋白溶解异常。
Hematol Cell Ther. 1996 Jul;38(3):279-84. doi: 10.1007/s00282-996-0279-2.
3
Plasma factor VII and thrombin-antithrombin III levels indicate increased tissue factor activity in sickle cell patients.血浆因子VII和凝血酶 - 抗凝血酶III水平表明镰状细胞病患者的组织因子活性增加。
Br J Haematol. 1992 Aug;81(4):539-44. doi: 10.1111/j.1365-2141.1992.tb02989.x.
4
Posttrauma coagulation and fibrinolysis.创伤后凝血与纤溶
Crit Care Med. 1992 May;20(5):594-600. doi: 10.1097/00003246-199205000-00009.
5
Thrombophilia in sickle cell disease: the red cell connection.镰状细胞病中的易栓症:红细胞的关联
Blood. 2001 Dec 1;98(12):3228-33. doi: 10.1182/blood.v98.12.3228.
6
Abnormalities of blood coagulation and fibrinolysis in psoriasis.
Dermatology. 1994;189(1):32-7. doi: 10.1159/000246755.
7
Hypercoagulability and hypofibrinolysis in sickle-cell disease.
Blut. 1975 Dec;31(6):355-60. doi: 10.1007/BF01634001.
8
Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.亚临床甲状腺疾病中的血液凝固、纤溶活性和血脂谱:亚临床甲状腺功能亢进会增加血浆凝血因子X活性。
Clin Endocrinol (Oxf). 2006 Mar;64(3):323-9. doi: 10.1111/j.1365-2265.2006.02464.x.
9
Activation of the fibrinolytic system and utilization of the coagulation inhibitors in sepsis: comparison with severe sepsis and septic shock.脓毒症中纤溶系统的激活及凝血抑制剂的利用:与严重脓毒症和脓毒性休克的比较
Intensive Care Med. 2001 Dec;27(12):1853-9. doi: 10.1007/s00134-001-1139-8. Epub 2001 Nov 10.
10
[Long-term hemodialysis and changes in variables of coagulation and fibrinolysis].[长期血液透析与凝血和纤溶变量的变化]
Fukuoka Igaku Zasshi. 1991 Nov;82(11):576-85.

引用本文的文献

1
Plasminogen activator inhibitor-2 and impaired fibrinolysis in pregnancy and sickle cell anemia.纤溶酶原激活物抑制剂-2 与妊娠和镰状细胞贫血中的纤溶功能障碍。
Arch Gynecol Obstet. 2024 Jun;309(6):2447-2458. doi: 10.1007/s00404-023-07121-6. Epub 2023 Jul 4.
2
Venous thromboembolism prophylaxis in sickle cell disease: a multicenter cohort study of adolescent inpatients.镰状细胞病中的静脉血栓栓塞预防:青少年住院患者的多中心队列研究。
Blood Adv. 2023 May 9;7(9):1762-1768. doi: 10.1182/bloodadvances.2022007802.
3
The Cardiopulmonary Complications of Sickle Cell Disease.
镰状细胞病的心肺并发症。
Hematol Oncol Clin North Am. 2022 Dec;36(6):1217-1237. doi: 10.1016/j.hoc.2022.07.014.
4
Endothelial dysfunction biomarkers in sickle cell disease: is there a role for ADMA and PAI-1?镰状细胞病中的血管内皮功能障碍生物标志物:ADMA 和 PAI-1 是否起作用?
Ann Hematol. 2022 Feb;101(2):273-280. doi: 10.1007/s00277-021-04695-6. Epub 2021 Oct 19.
5
Which adults with sickle cell disease need an evaluation for pulmonary embolism?哪些镰状细胞病的成年患者需要进行肺栓塞评估?
Br J Haematol. 2021 Nov;195(3):447-455. doi: 10.1111/bjh.17552. Epub 2021 Sep 1.
6
The different facets of sickle cell disease-related pulmonary hypertension.镰状细胞病相关肺动脉高压的不同方面。
Curr Opin Pulm Med. 2021 Sep 1;27(5):319-328. doi: 10.1097/MCP.0000000000000795.
7
Microfluidics in Sickle Cell Disease Research: State of the Art and a Perspective Beyond the Flow Problem.镰状细胞病研究中的微流控技术:现状与超越流动问题的展望
Front Mol Biosci. 2021 Mar 8;7:558982. doi: 10.3389/fmolb.2020.558982. eCollection 2020.
8
The molecular basis for the prothrombotic state in sickle cell disease.镰状细胞病中促血栓形成状态的分子基础。
Haematologica. 2020 Oct 1;105(10):2368-2379. doi: 10.3324/haematol.2019.239350.
9
Sickle Cell Disease: A Paradigm for Venous Thrombosis Pathophysiology.镰状细胞病:静脉血栓形成病理生理学的范例。
Int J Mol Sci. 2020 Jul 25;21(15):5279. doi: 10.3390/ijms21155279.
10
Life-Threatening Infectious Complications in Sickle Cell Disease: A Concise Narrative Review.镰状细胞病的危及生命的感染性并发症:简明叙述性综述
Front Pediatr. 2020 Feb 20;8:38. doi: 10.3389/fped.2020.00038. eCollection 2020.